PARP inhibitors upregulate the expression of immunosuppressive molecules, such as PD-L1, not only on cancer cells but also on TAMs, and augment the therapeutic benefits of immune checkpoint inhibitors in preclinical studies across a range of tumor types [398]. The gene discussed is CD274; the disease is cancer.